Oruka Therapeutics, Inc.
ORKA
$41.13
-$0.62-1.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 70.19% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 28.12% | -- | -- | -- | |
| Operating Income | -28.12% | -- | -- | -- | |
| Income Before Tax | -25.13% | -- | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -25.13% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -15.44% | -- | -- | -- | |
| EBIT | -28.12% | -- | -- | -- | |
| EBITDA | -82.36% | -- | -- | -- | |
| EPS Basic | 92.34% | -- | -- | -- | |
| Normalized Basic EPS | 75.88% | -- | -- | -- | |
| EPS Diluted | 92.34% | -- | -- | -- | |
| Normalized Diluted EPS | 75.88% | -- | -- | -- | |
| Average Basic Shares Outstanding | 193.90% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 191.70% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |